2 May 2016 - CADTH has received notice of a pending submission from Raptor Pharmaceutical for Quinsair (levofloxacin hemihydrate) oral solution for use by patients with cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections.

The submission is due later this month.

For more details, go to: https://www.cadth.ca/levofloxacin?utm_source=%2ALIVE%2A+CADTH%2FACMTS+Confirmed+Subscribers&utm_campaign=b551f6a09d-Call-for-PI-quinsair-5-02-2016&utm_medium=email&utm_term=0_2e3705996c-b551f6a09d-262951505